Is SCHD a Good ETF to Buy?
With around $65.7 billion in net assets, Schwab’s US Dividend…
Buy
63
MESO Quote, Financials, Valuation and Earnings
Last price:
$17.94
Seasonality move
:
27.71%
Day range:
$18.86 - $20.80
52-week range:
$1.61 - $22.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
196.60x
P/B ratio:
4.51x
Volume:
482.8K
Avg. volume:
570.2K
1-year change:
802.86%
Market cap:
$2.2B
Revenue:
$5.9M
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingMesoblast has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $11.00, Mesoblast has an estimated upside of 18.67% from its current price of $18.96.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $11.00 representing 100% downside risk from its current price of $18.96.
Fair Value
-
According to the consensus of 1 analyst, Mesoblast has 18.67% upside to fair value with a price target of $11.00 per share.
MESO vs. S&P 500
-
Over the past 5 trading days, Mesoblast has overperformed the S&P 500 by 6.46% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Mesoblast does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Mesoblast revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Mesoblast reported revenues of --.
Earnings Growth
-
Mesoblast has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Mesoblast reported earnings per share of --.
Enterprise value:
2.2B
EV / Invested capital:
--
Price / LTM sales:
196.60x
EV / EBIT:
--
EV / Revenue:
295.51x
PEG ratio (5yr expected):
--
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2022-06-30 | 2023-06-30 | |
| Income Statement | ||||||
| Revenue | $7.5M | $10.2M | $7.5M | $2.2M | $2.1M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$107.5M | -$80.8M | -$69.3M | -$20.3M | -$18.7M | |
| EBITDA | -$87.7M | -$70.8M | -$59.8M | -$16.1M | -$17.3M | |
| Diluted EPS | -$1.55 | -$63.40 | -$51.23 | -$31.59 | -$26.70 | |
| Period Ending | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $136.5M | $148.2M | $69.8M | $81.7M | $86.5M | |
| Total Assets | $733.6M | $744.7M | $662.1M | $669.4M | $669.2M | |
| Current Liabilities | $90.1M | $94.3M | $51.4M | $42M | $73.2M | |
| Total Liabilities | $184.3M | $163.3M | $165.1M | $167.6M | $188.8M | |
| Total Equity | $549.3M | $581.4M | $497M | $501.8M | $480.4M | |
| Total Debt | $89.5M | $94.2M | $96.6M | $108.8M | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$61.9M | -- | -- | -- | -- | |
| Cash From Investing | -$336K | -- | -- | -$127K | $23K | |
| Cash From Financing | $32.6M | -- | -- | -$3.2M | -$1.9M | |
| Free Cash Flow | -$62.2M | -- | -- | -- | -- | |
MESO
Sector
Market Cap
$2.2B
$48.9M
Price % of 52-Week High
86.18%
49.34%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
802.86%
-30.56%
Beta (5-Year)
3.357
0.754
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$19.17
200-day SMA
Buy
Level
$8.23
Bollinger Bands (100)
Buy
Level
6.24 - 13.4
Chaikin Money Flow
Buy
Level
16.8M
20-day SMA
Buy
Level
$15.22
Relative Strength Index (RSI14)
Buy
Level
63.58
ADX Line
Buy
Level
47.14
Williams %R
Neutral
Level
-29.2589
50-day SMA
Buy
Level
$12.11
MACD (12, 26)
Buy
Level
2.44
25-day Aroon Oscillator
Buy
Level
44
On Balance Volume
Neutral
Level
172.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.2683)
Buy
CA Score
(Annual)
Level (0.1562)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (0.6379)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
Stock Forecast FAQ
In the current month, MESO has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MESO average analyst price target in the past 3 months is $11.00.
-
Where Will Mesoblast Stock Be In 1 Year?
According to analysts, the consensus estimate is that Mesoblast share price will rise to $11.00 per share over the next 12 months.
-
What Do Analysts Say About Mesoblast?
Analysts are divided on their view about Mesoblast share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Mesoblast is a Sell and believe this share price will drop from its current level to $11.00.
-
What Is Mesoblast's Price Target?
The price target for Mesoblast over the next 1-year time period is forecast to be $11.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MESO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Mesoblast is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of MESO?
You can purchase shares of Mesoblast via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Mesoblast shares.
-
What Is The Mesoblast Share Price Today?
Mesoblast was last trading at $17.94 per share. This represents the most recent stock quote for Mesoblast. Yesterday, Mesoblast closed at $18.96 per share.
-
How To Buy Mesoblast Stock Online?
In order to purchase Mesoblast stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is NAIL a Good ETF to Buy?
If you’re thinking about buying the NAIL ETF, this article…
3 High Dividend Dow Jones Stocks
Thanks to surging stock prices over the past two years,…
Stock Ideas
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 125x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
NARI alert for Jan 7
Inari Medical [NARI] is up 22.25% over the past day.
Buy
70
PDEX alert for Jan 7
Pro-Dex [PDEX] is down 10.89% over the past day.
Buy
52
ALCO alert for Jan 7
Alico [ALCO] is down 3.89% over the past day.
